Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:945-952
Published online before print March 13, 2003, doi: 10.1161/01.ATV.0000066686.46338.F1
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v23,p1705)
Right arrow All Versions of this Article:
23/6/945    most recent
01.ATV.0000066686.46338.F1v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quinn, M. J.
Right arrow Articles by Plow, E. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quinn, M. J.
Right arrow Articles by Plow, E. F.
Related Collections
Right arrow Acute coronary syndromes
Right arrow Aggregation
Right arrow Platelet function inhibitors
Right arrow Platelets
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:945.)
© 2003 American Heart Association, Inc.


ATVB In Focus

Integrin {alpha}IIbß3 and Its Antagonism

Martin J. Quinn; Tatiana V. Byzova; Jun Qin; Eric J. Topol; Edward F. Plow

From the Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Departments of Cardiovascular Medicine (M.J.Q., E.J.T.) and Molecular Cardiology (T.V.B., J.Q., E.F.P.), Cleveland Clinic Foundation, Cleveland, Ohio.

Correspondence to Edward F. Plow, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Department of Molecular Cardiology/NB50, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail plowe{at}ccf.org

Series Editor: Lawrence Brass
ATVB In Focus Platelet Activation and the Formation of the Platelet Plug

Previous Brief Reviews in this Series:

•Tsai H-M. Deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. 2003;23:388–396.

{alpha}IIbß3, the major membrane protein on the surface of platelets, is a member of the integrin family of heterodimeric adhesion receptors. The {alpha}IIb and ß3 subunits are each composed of a short cytoplasmic tail, a single transmembrane domain, and a large, extracellular region that consists of a series of linked domains. Recent structural analyses have provided insights into the organization of this and other integrins and how a signal is initiated at its cytoplasmic tail to transform the extracellular domain of {alpha}IIbß3 into a functional receptor for fibrinogen or von Willebrand factor to support platelet aggregation and thrombus formation. These functions of {alpha}IIbß3 have been targeted for antithrombotic therapy, and intravenous {alpha}IIbß3 antagonists have been remarkably effective in the setting of percutaneous coronary interventions, showing both short-term and long-term mortality benefits. However, the development of oral antagonists has been abandoned on the basis of excess of mortality in clinical trials, and the extension of therapy with existing {alpha}IIbß3 antagonists to broadly treat acute coronary syndromes has not fully met expectations. An in-depth understanding of how antagonists engage and influence the function of {alpha}IIbß3 and platelets in the context of the new structural insights may explain its salutary and potential deleterious effects.


Key Words: platelets • acute coronary syndromes • aggregation • platelet function inhibitors




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Varga-Szabo, I. Pleines, and B. Nieswandt
Cell Adhesion Mechanisms in Platelets
Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 403 - 412.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
B. Nieswandt, M. Moser, I. Pleines, D. Varga-Szabo, S. Monkley, D. Critchley, and R. Fassler
Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo
J. Exp. Med., December 24, 2007; 204(13): 3113 - 3118.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Bassler, C. Loeffler, P. Mangin, Y. Yuan, M. Schwarz, C. E. Hagemeyer, S. U. Eisenhardt, I. Ahrens, C. Bode, S. P. Jackson, et al.
A Mechanistic Model for Paradoxical Platelet Activation by Ligand-Mimetic {alpha}IIb{beta}3 (GPIIb/IIIa) Antagonists
Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): E9 - E15.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
C.-L. Huang, J.-C. Cheng, A. Stern, J.-T. Hsieh, C.-H. Liao, and C.-P. Tseng
Disabled-2 is a novel {alpha}IIb-integrin-binding protein that negatively regulates platelet-fibrinogen interactions and platelet aggregation
J. Cell Sci., November 1, 2006; 119(21): 4420 - 4430.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W.-Y. Wang, Y.-C. Wu, and C.-C. Wu
Prevention of Platelet Glycoprotein IIb/IIIa Activation by 3,4-Methylenedioxy-beta-Nitrostyrene, A Novel Tyrosine Kinase Inhibitor
Mol. Pharmacol., October 1, 2006; 70(4): 1380 - 1389.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Brownlee
Inaugural Article: Biography of Barry S. Coller
PNAS, September 7, 2004; 101(36): 13111 - 13113.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Schwarz, Y. Katagiri, M. Kotani, N. Bassler, C. Loeffler, C. Bode, and K. Peter
Reversibility versus Persistence of GPIIb/IIIa Blocker-Induced Conformational Change of GPIIb/IIIa ({alpha}IIb{beta}3, CD41/CD61)
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1002 - 1011.
[Abstract] [Full Text] [PDF]